0001209191-17-049646.txt : 20170818
0001209191-17-049646.hdr.sgml : 20170818
20170818171734
ACCESSION NUMBER: 0001209191-17-049646
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20170818
DATE AS OF CHANGE: 20170818
EFFECTIVENESS DATE: 20170818
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp
CENTRAL INDEX KEY: 0001533040
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-293158
FILM NUMBER: 171041702
BUSINESS ADDRESS:
STREET 1: 257 SIMARANO DRIVE
STREET 2: SUITE 101
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
BUSINESS PHONE: (508) 767-3861
MAIL ADDRESS:
STREET 1: 257 SIMARANO DRIVE
STREET 2: SUITE 101
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
D
1
primary_doc.xml
X0708
D
LIVE
0001533040
RXi Pharmaceuticals Corp
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
(508) 767-3861
DELAWARE
None
None
Corporation
true
Geert
Cauwenbergh
c/o RXi Pharmaceutials Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Executive Officer
Director
Gerrit
Dispersyn
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Executive Officer
Alexey
Eliseev
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Executive Officer
Robert
Bitterman
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Keith
Brownlie
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Paul
Dorman
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Jonathan
Freeman
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Curtis
Lockshin
c/o RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 10
Marlborough
MA
MASSACHUSETTS
01752
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2017-08-08
true
true
false
0
15261000
261000
15000000
450,000 shares issued to LPC on 8/8/17 as initial consideration for put right granted to RXi under equity line; valued for purposes of this form at $0.58/share (closing stock price on 8/8/17 on NASDAQ Capital Market).
false
1
0
0
0
false
RXi Pharmaceuticals Corporation
Geert Cauwenbergh
Geert Cauwenbergh
President and CEO
2017-08-18